US OptionsDetailed Quotes
ITOS250117P8000
- 0.35
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.35High0.35Low
0.35Open0.35Pre Close7 Volume7.19K Open Interest8.00Strike Price245.00Turnover37.86%IV1.42%PremiumJan 17, 2025Expiry Date0.24Intrinsic Value100Multiplier6DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type-0.7198Delta0.8870Gamma25.87Leverage Ratio-0.0101Theta-0.0009Rho-18.62Eff Leverage0.0034Vega
ITeos Therapeutics Stock Discussion
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet